Hilltop Holdings Inc. Has $256,000 Stock Position in Baxter International Inc (NYSE:BAX)
Hilltop Holdings Inc. lessened its holdings in Baxter International Inc (NYSE:BAX) by 5.5% in the fourth quarter, HoldingsChannel reports. The fund owned 3,064 shares of the medical instruments supplier’s stock after selling 177 shares during the period. Hilltop Holdings Inc.’s holdings in Baxter International were worth $256,000 as of its most recent filing with the SEC.
Several other institutional investors have also made changes to their positions in the company. Colony Group LLC grew its stake in Baxter International by 3.2% in the third quarter. Colony Group LLC now owns 193,679 shares of the medical instruments supplier’s stock worth $16,941,000 after purchasing an additional 5,942 shares in the last quarter. State Street Corp raised its position in Baxter International by 2.6% during the 3rd quarter. State Street Corp now owns 24,189,517 shares of the medical instruments supplier’s stock valued at $2,120,911,000 after purchasing an additional 620,579 shares in the last quarter. Chevy Chase Trust Holdings Inc. lifted its holdings in shares of Baxter International by 7.6% in the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 430,292 shares of the medical instruments supplier’s stock worth $37,638,000 after buying an additional 30,516 shares during the period. Equitable Trust Co. lifted its holdings in shares of Baxter International by 2.3% in the 3rd quarter. Equitable Trust Co. now owns 165,027 shares of the medical instruments supplier’s stock worth $14,435,000 after buying an additional 3,691 shares during the period. Finally, EP Wealth Advisors LLC purchased a new stake in shares of Baxter International in the 3rd quarter worth $520,000. 83.10% of the stock is owned by institutional investors.
NYSE:BAX opened at $73.57 on Thursday. Baxter International Inc has a 52 week low of $69.10 and a 52 week high of $95.00. The firm has a 50 day moving average of $85.94 and a 200 day moving average of $85.14. The company has a quick ratio of 1.81, a current ratio of 2.32 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $37.49 billion, a price-to-earnings ratio of 22.23, a PEG ratio of 1.77 and a beta of 1.00.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 1st. Stockholders of record on Friday, February 28th will be given a $0.22 dividend. The ex-dividend date of this dividend is Thursday, February 27th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 1.20%. Baxter International’s payout ratio is 26.59%.
Several equities analysts have recently commented on the company. Deutsche Bank cut their price target on Baxter International from $109.00 to $99.00 and set a “buy” rating on the stock in a research note on Wednesday, March 18th. Raymond James lowered their price objective on shares of Baxter International from $95.00 to $90.00 and set an “outperform” rating for the company in a research note on Wednesday, March 18th. Stifel Nicolaus raised shares of Baxter International from a “hold” rating to a “buy” rating and upped their price objective for the stock from $87.00 to $95.00 in a research note on Thursday, March 19th. TheStreet cut shares of Baxter International from a “b+” rating to a “c+” rating in a report on Wednesday, March 18th. Finally, Credit Suisse Group cut their price objective on shares of Baxter International from $98.00 to $96.00 and set an “outperform” rating on the stock in a report on Wednesday, March 18th. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $92.16.
Baxter International Company Profile
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Recommended Story: What is quantitative easing?
Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.